Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients

Research output: Contribution to journalArticle

6 Citations (Scopus)
263 Downloads (Pure)

Abstract

Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction. In an area where there have been limited pharmacological advances in the last 10 years, this drug was a game changer and a much welcomed addition to contemporary heart failure therapy. It is currently being studied in patients with heart failure with preserved ejection fraction and for the reduction of heart failure events post-acute myocardial infarction. Results from the ongoing PARADISE-MI study are awaited by the global cardiology community with great interest.

Original languageEnglish
Pages (from-to)545-551
Number of pages7
JournalDrugs of Today
Volume53
Issue number10
DOIs
Publication statusPublished - Oct 2017

Keywords

  • Sacubitril/valsartan
  • LCZ-696
  • Heart failure
  • Myocardial infarction

Fingerprint Dive into the research topics of 'Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients'. Together they form a unique fingerprint.

  • Cite this